Brief: Virpax Pharmaceuticals Inc Advances Envelta Development With Ncats Under Crada Agreement
10/11/2021 15:10
Nov 10 (Reuters) - Virpax Pharmaceuticals Inc VRPX.O :
* VIRPAX PHARMACEUTICALS INC - ADVANCES ENVELTA DEVELOPMENT
WITH
NCATS UNDER CRADA AGREEMENT
* VIRPAX PHARMACEUTICALS INC - MULTIPLE CONTRACTS AWARDED TO
SUPPORT DEVELOPMENT AND MANUFACTURING OF ENVELTA (NES100)
Source text for Eikon: ID:nBw1V9RrLa
Further company coverage: VRPX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Virpax Pharmaceuticals
See all newsVirpax Pharma plunges as Nasdaq delisting looms
Brief: Virpax Pharmaceuticals Files For Offering On Best Efforts Basis Up To 2.4 Million Shares Of Common Stock
Brief: Virpax receives positive Probudur™ results for dose range study
Brief: Virpax Looking To Use Met To Develop Intranasal Covid Vaccine
Brief: Virpax Confirms Positive Results With Us Army With Probudur™ For Combat Care Study